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ABSTRACT
Twist1 and Twist2 are highly conserved members of
the Twist subfamily of bHLH proteins responsible
for the transcriptional regulation of the develop-
mental programs in mesenchymal cell lineages.
The regulation of such processes requires that
Twist1 and Twist2 function as molecular switches
to activate and repress target genes by employing
several direct and indirect mechanisms. Modes
of action by these proteins include direct DNA
binding to conserved E-box sequences and re-
cruitment of coactivators or repressors, seques-
tration of E-protein modulators, and interruption
of proper activator/repressor function through
protein–protein interactions. Regulatory outcomes
of Twist1 and Twist2 are themselves controlled
by spatial-temporal expression, phosphoregulation,
dimer choice and cellular localization. Although
these two proteins are highly conserved and
exhibit similar functions in vitro, emerging literature
have demonstrated different roles in vivo. The
involvement of Twist1 and Twist2 in a broad
spectrum of regulatory pathways highlights the
importance of understanding their roles in normal
development, homeostasis and disease. Here we
focus on the mechanistic models of transcriptional
regulation and summarize the similarities and differ-
ences between Twist1 and Twist2 in the context
of myogenesis, osteogenesis, immune system
development and cancer.
INTRODUCTION
The basic helix–loop–helix (bHLH) family of proteins
comprises a series of transcription factors that act as
master regulators on different tissues. Their complex regu-
latory functions make them ﬁne-tuned machinery for
controlling cell fate at the early stages of embryogenesis.
The hallmark for DNA binding of bHLH transcription
factors is the formation of a bipartite DNA-binding
domain created when two of these factors form homo or
heterodimer complexes through their HLH motifs
allowing the basic stretch of amino acids to contact the
DNA. This DNA-binding domain is able to recognize cis
regulatory elements containing the consensus sequence
50-NCANNTGN-30 (termed E-box). E-boxes are found
in the regulatory regions of many lineage speciﬁc genes,
which account for the numerous pathways regulated by
these transcription factors (1–3).
The bHLH transcription factors are classiﬁed into three
major classes: the ubiquitous Class A bHLH factors that
include E2-2, HEB and the two isoforms of the E2A gene
E12/E47 (also known as E proteins); the tissue-restricted
Class B bHLH factors; and the inhibitory HLH proteins,
constituted by the Id proteins, which lack the basic region
used to contact DNA. The Twist proteins form a subfam-
ily of the Class B bHLH factors. These include Paraxis (1),
Scleraxis (4), Hand1 (5), Hand2 (6), Twist1 and Twist2. In
this family of transcription factors, Twist1 and Twist2
exhibit a high degree of sequence similarity suggesting
that their functions might be redundant. These proteins
also exhibit bifunctional roles as activators and repressors
of gene transcription making the characterization of their
individual modes of action a complex task (7,8). It is
therefore the focus of this review to highlight the
*To whom correspondence should be addressed. Tel: 787 7582525 (Ext. 1372); Fax: 787 7644209; Email: carmen.cadilla@upr.edu
The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
Published online 8 October 2010 Nucleic Acids Research, 2011, Vol. 39, No. 4 1177–1186
doi:10.1093/nar/gkq890
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.similarities between Twist1 and Twist2 and distinguish
when their functions as gene regulators are unique.
Twist1
The ﬁrst Twist protein to be described was the Drosophila
Twist (DTwist) as one of the zygotic genes required for
dorso-ventral patterning during embryogenesis (9). As
such, it is a key regulator for gastrulation and subsequent
mesoderm formation, where differential expression
patterns of DTwist have been observed. DTwist was pri-
marily thought to be an activator based on its role in
deﬁning the dorsoventral axis in parallel with the
Drosophila NF-kB homolog Dorsal, and driving gastrula-
tion synergistically with Snail. It is now known that
DTwist can form both homodimers and heterodimers
with the Drosophila E-protein Daughterless, making it
either a transcription activator or repressor (10,11).
Although DTwist induces cellular differentiation in
Drosophila, the classical roles of Twist1 and Twist2
proteins in mammals are to inhibit differentiation of
mesenchymal cell lineages, notably muscle and bone.
Mammalian Twist1 was identiﬁed in mouse by its high
similarity with DTwist, having 48% amino-acid identity,
and was ﬁrst described as a repressor of gene transcription
due to its role in the inhibition of myogenesis and osteo-
genesis (12–14). Mutations in Twist1 cause Saethre–
Chotzen syndrome (SCS; OMIM 101400) that is
characterized by premature closure of the calvarial
sutures, or craniosynostosis (15,16). The various muta-
tions found in SCS patients give rise to Twist1 loss of
function, protein instability and improper localization
(17). A Twist1-KO mouse was shown to be embryonic
lethal and displayed abnormalities in neural tube closure
(18). The lethality of the Twist1 knockout mouse led to the
development of a Cre-mediated conditional knockout
mouse to help study the regulatory functions of Twist1
post-neural crest cell migration (19). A Twist1-null hetero-
zygous mouse has also been developed that presents a
Saethre-Chotzen syndrome-like phenotype (20), thus
providing an animal model for studying the SCS
craniosynostosis phenotype.
Twist2
Twist2 was ﬁrst identiﬁed from a yeast-two-hybrid screen
using E12 as bait, and it was named Dermo1 for its ex-
pression pattern in the dermis of mouse embryos (21).
Dermo1 was later renamed Twist2 based on its high
homology and overlapping expression pattern with
Twist1, and as seen with Twist1, it was found to inhibit
both myogenic and osteoblast maturation (21–23). During
mammalian embryogenesis, Twist2 is expressed in meso-
dermal tissues, although temporally expressed after
Twist1. The Twist2-KO mouse presents relatively normal
embryonic development and no notable bone
abnormalities, but typically dies 2–3 days after birth due
to cachexia, failure to thrive and high levels of
pro-inﬂammatory cytokines (22). It is important to note
that the Twist2-KO mouse was developed in an inbred
129/Sv background and that the same Twist2-KO mouse
in a 129/C57 mixed background survives with only a mild
phenotype suggesting the existence of modiﬁer genes in
these different genetic backgrounds (22). Recently it has
been shown that two homozygous nonsense mutations
(c.324C>T and c.486C>T) in TWIST2 cause Setleis
Syndrome (MIM 227260) (24). Setleis syndrome is an
inherited developmental disorder classiﬁed as a Focal
Facial Dermal Dysplasia type III (FFDD III) and is
characterized by bilateral temporal marks and additional
facial features, including, absent eyelashes on both lids or
multiple rows on the upper lids, absent Meibomian
glands, slanted eyebrows and chin clefting (24). These mu-
tations truncate the TWIST2 protein in glutamines 65 and
119 resulting in C-terminal domain mutants (Figure 1).
Examination of the Twist2 KO mouse developed in the
129/C57 mixed genetic background has revealed a facial
phenotype similar to that of Setleis syndrome patients and
has been established as a relevant mouse model for the
study of FFDD’s (24). Although human TWIST1 and
TWIST2 encode bHLH transcription factors with a high
degree of sequence identity, the ﬁnding that TWIST2 re-
cessive mutations cause an FFDD and dominant TWIST1
mutations causes Saethre–Chotzen craniosynostosis
suggests that these two genes exhibit non-redundant
functions in skin and bone development and highlights
Figure 1. Amino acid sequence alignment between Twist1 and Twist2. The functional motifs are delineated with black bars. Similarity between the
two proteins increases from 54% in the N-terminus to 95% in the bHLH region and 100% in the C-terminal Twist Box. Conserved threonine and
serine phospho-regulated residues involved in dimer choice and DNA-binding site selection are indicated (27), and protein–protein interaction
domains characterized for Twist1 are located above the alignment. It is interesting to note that the Twist box has been characterized as both an
activation domain with the amino-acid motif LX3FX3R (indicated in red) (8) and as a repressor domain (25).
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entities (24).
Twist2 is 66% identical to Twist1 and identity increases
to 98% in the basic and HLH regions of the proteins
(Figure 1). The major differences between both proteins
are found in the N-terminal region, where Twist1 has
two glycine-rich tracks that are absent in Twist2, making
Twist1 a bigger protein than Twist2 by having 202 amino
acids versus 160 amino acids respectively. The glycine-rich
motifs found in Twist1 may be used to interact with
proteins that are not bound by Twist2 leading to differ-
ences in protein function (Figure 1). The last 20 amino
acids at the C-terminus contain a repressor domain
termed ‘Twist box’ which is identical in both Twist1 and
Twist2 and not found in other Twist subfamily members
(25). A transactivation domain has also been characterized
within the Twist box, containing amino-acid residues
Leu-187, Phe-191 and Arg-195 (LX3FX3R) in Twist1,
which are completely conserved throughout the animal
kingdom (8). At the gene level, Twist1 and Twist2 share a
common intron/exon organization that likely reﬂects an
evolutionary gene duplication event (14,24).
This review will ﬁrst focus on the factors that inﬂuence
regulatory outcomes of Twist1 and Twist2, and the
various mechanisms described for controlling gene expres-
sion. In addition, speciﬁc developmental programs
regulated by Twist1 and Twist2, such as myogenesis and
osteogenesis will help illustrate the diverse mechanisms of
action. Finally, the role of Twist1 and Twist2 in inﬂam-
matory disorders and cancer will be discussed.
GENERAL MODES OF TRANSCRIPTIONAL
ACTIVATION AND REPRESSION
There are several factors that inﬂuence the function
of Twist1 and Twist2. These include dimer choice,
phosphoregulation, protein–protein interactions and
spatial-temporal expression. Dimer choice is mainly
inﬂuenced by the availability of other bHLH proteins
within the cell and the phosphorylation state of these
proteins (26–28). It is known that Class B bHLH factors
can form functional homodimers as well as heterodimers
with Class A bHLH factors including E12/E47. However,
heterodimer formation among class B bHLH proteins has
also been reported as in the case with Twist1 and Hand2
dimer formation (Figure 2D) (6,29). Id proteins have great
afﬁnity for E12 and compete against class B bHLH
proteins for E12 binding (26,28,30). Therefore, Id
proteins actively alter dimerization pools by binding and
sequestering bHLH factors, without themselves being able
to bind DNA. The composition of these partner pools will
ultimately determine the expression proﬁle and therefore
the cellular response. Hence, the relative stoichiometry of
these factors inﬂuence whether Twist1 or Twist2 form
heterodimers with E12, or homodimer formation is
favored due to Id-mediated E12 sequestration.
Partner choice can also be regulated by the phosphor-
ylation state of speciﬁc threonine and serine residues that
are conserved in the ﬁrst a-helix of the HLH domain of
Twist proteins (Figure 1). Threonine 125 and serine 127 of
Twist1 are conserved from DTwist throughout the Twist
subfamily of proteins (6). The phosphorylation state
is determined by protein kinase A and C, and protein
phosphatase 2A (29). Interestingly, mutations of these
phosphoregulated residues not only alter partner choice
but additionally alter E-box-binding afﬁnity (Figure 2D)
(31). Recently, PKB/AKT has also been linked to the
phosphorylation of Twist1 at serine 42 (32). Hence,
the difference in functions of Twist homodimers and
Twist1/E-protein heterodimers could be in part explained
by changes in E-box afﬁnity due to phosphorylation state.
The ubiquitous E-proteins can also be phosphoregulated,
contributing to an additional level of regulation of
these proteins. For example, phosphorylation of E47 is
required for heterodimerization with the myogenic
bHLH protein MyoD to occur (33). However, the
phosphoregulated residue on E47 is not found in the
ﬁrst helix like in Twist1 and Twist2 but rather on serine
140, which is found in the N-terminus. Nonetheless, the
phosphorylation status of these proteins contributes to the
dynamics of bHLH protein function.
Many of the target genes of mammalian Twist1 and
Twist2 have multiple E-boxes in their promoter regions.
Therefore dimer choice could inﬂuence E-box selection,
which, with combinatorial binding of other bHLH tran-
scription factors, will ultimately control transcriptional
outcomes. Direct mechanisms of gene activation by
Twist1 and Twist2 usually require cis-binding to E-boxes
found in the regulatory regions of target genes. Once
bound, these factors provide a surface that can recruit
other co-activators to form an open chromatin conform-
ation for the assembly of the transcriptional machinery.
The C-terminal domain described for Twist1 is required
for gene activation (Figure 1). By fusing this transacti-
vation domain to another DNA-binding protein, it was
possible to demonstrate that the C-terminal domain of
Twist1 was sufﬁcient and necessary to activate transcrip-
tion (8). Therefore, C-terminal domain mutants could
result in dominant negative mutants by sequestering
E-proteins or by non-functional binding to E-boxes.
Indirect mechanisms of transcriptional activation usually
involve sequestration of repressors or other bHLH
proteins poised for inhibition, activation of another tran-
scription factor, or through cross-talk with other gene
regulators through protein/protein interactions (12,34).
The mechanisms of repression for Twist1 and Twist2
include E-protein titration (mimicking Id protein seques-
tration), blocking the DNA binding and/or the action of
other transcription activators, binding E-boxes as
heterodimers with E-proteins, and recruitment of histone
deacetylases (HDAC) (Figure 2). Dimerization of Twist
with E-proteins to form inhibitory complexes usually
occurs through the HLH domain, however, the
N-terminal domain as well as the C-terminal domain are
known to bind and block the transactivation activity of
other transcription factors, or to form multi-protein
repressor complexes (22,25,35).
An attractive paradigm has emerged in the literature
in which repression and activation by these proteins
depends on dimer choice, and that Twist homodimers typ-
ically activate transcription while heterodimers function
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Drosophila development where D-Twist homodimers
drove gene activation while D-Twist/Daughterless
heterodimers were associated with gene repression (10).
However, this paradigm has been challenged in mamma-
lian systems where Twist1/E12 heterodimers were found
to be responsible for both the activation and repression of
separate genes within the same cells (28). Interestingly,
murine Twist1/E12 heterodimers were able to drive ex-
pression of a Drosophila-derived reporter construct that
was activated by Drosophila Twist homodimers (8).
Although all of the regulatory mechanisms employed by
Twist1 and Twist2 have yet to be elucidated, their func-
tions have been studied in several well-characterized
Figure 2. Modes of transcriptional regulation by Twist1 and Twist2. The Twist1 (TW1) and Twist2 (TW2) bHLH transcription factors exhibit a
bifunctional role by acting as activators and repressors depending on post-translational modiﬁcations, partner choice and cellular context (6,7,28).
(A) The mode of action employed by Twist1 and Twist2 was ﬁrst understood in genes involved in muscle development. The myogenic bHLH factors
such as MyoD bind as heterodimers with E-proteins to E-boxes found in regulatory regions of muscle-speciﬁc genes. MyoD-mediated activation
typically requires the binding of MEF2 and involves the recruitment of HATs. Twist acts as a repressor by promoting deacetylation either by
blocking HAT activity or recruiting HDACs (35,38). (B) The role of Twist during osteogenesis was highlighted when mutations of Twist1 were
identiﬁed in SCS patients. Based on the SCS mouse model and studies in human osteoblasts, it was determined that Twist1 acted before Twist2 on
osteoblast maturation (20,23). Twist1, as a heterodimer with E12, represses the FGFR2 gene, and as Id protein levels rise, E12 gets sequestered
leading to Twist1 homodimerization. As a homodimer, Twist1 activates FGFR2 which mediates downstream activation of RunX2 (26,42). Aside of
FGF signaling, both Twist1 and Twist2 can block the transactivation activity of the master regulator RunX2 (25). (C) Twist can repress genes
independent of DNA binding. For example, Twist can sequester E12 or MyoD leading to the repression genes of the myogenic program. By doing
so, Twist mimics the mechanism of inhibition employed by the Id proteins. (D) Twist partner choice can be determined by the phosphorylation state
of these proteins leading to homodimerization, or heterodimerization with Class A and Class B bHLH factors. E-box selection can also be inﬂuenced
by phosphoregulation. In this case, afﬁnity for a class B bHLH factor, Hand2, is favored when Twist1 is phosphorylated by PKA (29,31). (E) The
Twist2 KO mouse suggests a role of Twist2 in regulating cytokine gene expression (22). This work lead to a proposed negative feedback loop in
which inﬂammatory cytokines activate NF-kB, and NF-kB activates the expression of cytokines and both Twist1 and Twist2. In turn, Twist1 and
Twist2 can block the transactivation activity of NF-kB in a promoter-speciﬁc matter (45).
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Twist1 and Twist2 function in these systems.
INHIBITION OF MUSCLE DIFFERENTATION
The best understood example of inhibition by Twist1 and
Twist2 is the repression of the muscle differentiation
program, which is activated by the myogenic bHLH
subfamily of proteins composed of MyoD, myogenin,
Myf5 and MRF4. Muscle program inhibition integrates
several repression mechanisms carried out by both Twist1
and Twist2 (Figure 2A and C). Activation of muscle-
speciﬁc genes, like the muscle creatine kinase (MCK)
gene promoter, occurs through heterodimers between
myogenic bHLH proteins and E-proteins. Therefore,
sequestration of E-proteins by increased Twist1 and/or
Twist2 levels functions to inhibit muscle speciﬁc gene
activation (Figure 2C) (35,36). Id proteins also compete
for E protein binding with MyoD, Twist1 and Twist2,
adding an additional level of regulation for dimer forma-
tion. This provides a speciﬁc example of how HLH protein
levels at any given time can inﬂuence partner choice and
therefore affect gene expression.
For promoters like MCK, the myocyte enhancer factor
2 (MEF2) is needed as a co-activator in addition to the
myogenic bHLH proteins. There are two consensus MEF2
sites found in the MCK promoter, one of which is in close
proximity to the MCK right E-box bound by MyoD/E12,
allowing MEF2 and MyoD/E12 to act synergistically.
Inhibition of MEF2 action by Twist1 and Twist2 is not
mediated through E-protein titration, as is the case for
MyoD inhibition, but rather through physical interactions
that preclude the transactivation activity of MEF2 (35,36).
It is currently not known whether MEF2/Twist inter-
action inhibits DNA binding by MEF2 or if it precludes
the transactivation activity of MEF2 (35,36).
Furthermore, these proteins may use different mechanisms
as Twist1 requires the bHLH domain and the C-terminus
for MEF2 inhibition (36), while Twist2 requires only the
N-terminus and the C-terminus (35) which argues against
redundancy in Twist protein function.
Direct interaction of Twist1 with MyoD occurs through
the basic and the HLH domains of both proteins, and
functions to inhibit MyoD transactivation (Figure 2D)
(37). This mechanism of repression might be exclusive of
Twist1 since Twist2 has not been shown to interact with
MyoD in the same manner. Three arginine residues (R120,
122 and 124) found in the basic region of Twist1 are
required for the interaction and inhibition of MyoD
(37). However, mutation of these three arginine residues
in the Twist2 basic region presented no effect on MyoD
function indicating that only Twist1 binds MyoD (35).
Finally, chromatin modiﬁcations could be involved
in MyoD-MEF2 inhibition. It is known that MyoD acts
synergistically with the histone acetyltransferase (HAT)
p300 to activate muscle-speciﬁc gene targets. Twist1
binds and inhibits the HAT domains of both p300 and
PCAF (38) (Figure 2A). Physical interactions between
Twist1 and p300/PCAF are mediated through the
N-terminal region of Twist1, where the glycine rich
tracks are present (Figure 1) (38). The absence of the
glycine rich tracks in Twist2 might explain its inability
to inhibit HAT activity (39). The ﬁnding that Twist1 can
block HAT activity suggests that it might regulate gene
expression by modulating histone acetylation states and
thus altering chromatin conformation.
Although Twist2 does not inhibit HATs, it can however
alter chromatin conformational states by the recruitment
of histone deacetylases (HDAC). For example, Twist2
requires HDAC for MyoD-MEF2 inhibition since
Twist2-dependent repression can be relieved by treatment
with HDAC inhibitors (35). It is now known that both
Twist1 and Twist2 can interact with HDAC’s to exert
transcriptional repression (40,41).
REGULATION OF THE OSTEOBLASTIC PROGRAM
Identiﬁcation of Twist1 mutations associated with
Saethre-Chotzen syndrome (SCS) and the phenotype pre-
sented by the Twist1 null heterozygous mouse has
generated interest in the role of Twist1 during osteoblast
differentiation (17). The study of the Twist1 null hetero-
zygous mouse, as a model for SCS, provides an example of
how bHLH partner choice inﬂuences gene regulatory
outcomes. Both SCS patients and the Twist1
+/– mouse
have low Twist1 levels, thus altering the available bHLH
partner pool and contributing to the molecular pathology
of SCS. The haploinsufﬁciency of Twist1 decreases the
ability of Twist1 to compete with Id proteins for E12
dimerization, resulting in higher levels of Twist1
homodimers within the calvarial sutures (28). In this
diseased state, higher levels of Id proteins in comparison
to Twist1 favors the formation of Id/E12 heterodimers.
Therefore, sequestration of available E12 by Id precludes
the formation of Twist1/E12 heterodimers that favors
Twist1 homodimerization (Figure 2B). The regulation of
ﬁbroblast growth factor receptors (Fgfrs) constitutes an
important pathway in controlling cranial bone formation
(42). The higher ratio of Twist1 homodimers versus
heterodimers in Twist
+/– mice causes abnormal activation
of the ﬁbroblast growth factor receptor-2 (Fgfr2) gene
(26), resulting in expansion of the osteogenic fronts and
suture closure. Thus, the modulation of E-protein and/or
Id protein levels in Twist1
+/– mice can restore the normal
balance between homo and heterodimers and prevents
craniosynostosis (26). These ﬁndings challenge the clas-
sical view that Twist1 merely prevents osteoblast differen-
tiation, by suggesting that Twist1/E12 heterodimers
maintain the cells in a preosteoblast state through the
inhibition of Fgfr2, and as differentiation continues, a
switch to increased levels of Twist1 homodimers
promotes osteoblast maturation through the activation
of Fgfr2 (26).
In addition to craniosynostosis, SCS patients and
Twist1 haploinsufﬁcient mice present limb abnormalities.
As mentioned above, Twist1 and Hand2 can form
heterodimers between themselves, and their expression
patterns overlap in the developing limb (6). It was found
that overexpression of Hand2 could phenocopy the limb
abnormalities observed in Twist1 haploinsufﬁciency
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and Hand2 (6). The intercross of Twist1
+/– and Hand2
+/–
mice resulted in normal limb patterning thus rescuing the
phenotype by rebalancing the dimer pool (6). Gene dosage
and phosphoregulation have been found to inﬂuence the
interaction between Twist1 and Hand2. The
phosphorylated form of Twist1 has higher afﬁnity for
Hand2 while the dephosphorylated form of Twist1
favors homodimerization (Figure 2D) (6). Interestingly,
some mutations that cause SCS disrupt protein kinase A
(PKA) recognition sites on Twist1 (6), thus altering its
phosphorylation state and changing Twist1 partner
choice.
Twist2 is also known to regulate osteoblast differenti-
ation, however its involvement occurs temporally after
Twist1 (23). There are no known mutations in Twist2
associated to SCS-like phenotypes, hence the Twist2
appears to have no role in cranial bone development,
which is consistent with its lack of expression in develop-
ing skull (21).
The transcription factor Runx2 is considered a master
regulator of the osteogenic program due to its indispens-
able role in the regulation of most of the genes that give
rise to the mature osteoblast phenotype (25). It has been
demonstrated that Twist1 and Twist2 are involved in the
modulation of Runx2 function at the transcriptional level
as well as at the protein level (25,34,42–44). Twist1 is
proposed to be a transcriptional activator of the RUNX2
gene when immortalized human calvarial osteoblasts from
SCS patients were shown to have reduced levels of Runx2
mRNA and protein (43). EMSA analysis using nuclear
extracts from SCS patient calvarial osteoblasts resulted
in reduced DNA binding to a cis element found in the
promoter of the Runx2 target gene osteocalcin (OC) sug-
gesting decreased expression of Runx2 in SCS patients
(43). Other groups have used chromatin immunopre-
cipitation (ChIP) assays to demonstrate that both Twist1
and Twist2 can bind to the Runx2 promoter, although
this binding was not correlated to changes in Runx2
expression (34). The mechanisms by which Twist haploin-
sufﬁciency alters osteoblast differentiation has therefore
been attributed to indirect regulation of Runx2 through
the action of Fgfr2 (Figure 2B) (42). Twist1 directly binds
to the promoter of Fgfr2 and overexpression of Twist1
restores expression of Fgfr2, Runx2 and Runx2-regulated
genes in Twist1 mutant osteoblasts (42). Concurrently,
overexpression of Fgfr2 in Twist1 mutant calvarial osteo-
blasts rescued expression of Runx2. In this model of
indirect activation of Runx2 expression through Fgfr2, it
was also concluded that Runx2 exhibits a positive
feedback relationship with Fgfr2 (42). As stated above,
formation of Twist1 homodimers results in different
outcomes when compared to heterodimers with E12.
Therefore it is critical to consider the stoichiometric rela-
tionship of all of the available dimer partners within the
cell under study. To this extent, Twist1 partner choice
might determine Runx2 action since Fgfr2 is activated
by Twist1 homodimers and inhibited by Twist1
heterodimers (Figure 2B) (26).
Both Twist1 and Twist2 can also regulate Runx2 at the
protein level by physically interacting with Runx2 and
inhibiting its ability to bind DNA (Figure 2B) (25). It
was found that the antiosteogenic function of Twist1/2
is mediated through the C-terminal Twist box
(Figure 1). This region was found critical for Runx2 inter-
action since mutation of Serine 192 to Proline within the
Twist box of Twist1 resulted in poor interaction with
Runx2. The mice harboring this mutation were termed
Charlie Chaplin (CC/+) and displayed a craniosynostosis
phenotype with limb polydactyly highlighting the import-
ance of the Twist box for dictating proper bone formation.
The same study showed that expression of Runx2 was
unaffected in the Twist1-null heterozygous mouse and
attributed premature ossiﬁcation of the calvarial sutures
to the inability of Twist1 to inhibit Runx2 transactivation
(25). Twist1 heterozygosity reverses skull abnormalities
in Runx2
+/– mice while Twist2 heterozygosity reverses
clavicular abnormalities, indicating different genetic
interactions between both Twist1/2 and Runx2 (25).
ROLE IN IMMUNE SYSTEM DEVELOPMENT
AND RESPONSE
One of the most signiﬁcant phenotypes of the Twist2 KO
mouse is the perinatal death induced by high levels of
pro-inﬂammatory cytokines. As mentioned above,
Twist2 KO mice exhibit normal development until birth
but die 2–3 days after. Failure to thrive in these mice is
caused by cachexia that is manifested by severe wasting
of body tissue, loss of appetite and anemia (22). It has
been demonstrated that Twist1 and Twist2 modulate the
expression of proinﬂammatory cytokines through inhib-
ition of NF-kB mediated transactivation (Figure 2E).
Immunoprecipitation assays were used to demonstrate
that Twist1 and Twist2 physically interact with NF-kB
suggesting a possible mechanism for this repression. The
activation of Twist1/2 by NF-kB and their physical inter-
action is evolutionarily conserved. Based on this data, a
negative feedback loop has been proposed where cyto-
kines activate NF-kB and downstream activation of
Twist1/2 results in repression of NF-kB transactivation
(Figure 2E) (45). Twist1 and Twist2 are also known to
bind to E boxes in the promoters of cytokines regulated
by NF-kB such as TNFa and Il-1b (22). Further studies
have shown that Twist2 exhibits bifunctionality in the
regulation of cytokines by inhibiting the production of
pro-inﬂammatory cytokines such as interleukin-12
(IL-12) and interferon-g (IFNg) while promoting the
anti-inﬂammatory cytokine IL-10 (7).
One of the major characteristics of cachexia is severe
wasting of body tissue that can be attributed to deregula-
tion of energy homeostasis. Interestingly, Twist1 and
Twist2 have been characterized as critical regulators of
energy homeostasis involving adipose tissue (46,47). It
has been demonstrated that Twist2 acts as a physical
inhibitor of the transcription factor ADD1/SREBP1c
involved in adipocyte differentiation as well as regulation
of the LDL receptor gene, fatty acid and sterol biosynthe-
sis genes (48). Also, local chronic inﬂammation has been
linked to insulin resistance in adipose tissue (49), there-
fore, Twist1 and Twist2 involvement in proinﬂammatory
cytokine regulation and inhibition of ADD1/SREBP1c by
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the Twist2 KO mouse.
Twist1 and Twist2 are also key regulators of the
development of immune cells (7,41,50,51). For example,
Twist2 is a key negative regulator of myeloid lineage
development by inhibiting the proliferation and differen-
tiation of macrophage progenitors (7). Twist2 repression
of macrophage proliferation is mediated by direct inter-
action and inhibition of the transcription factors Runx1
and C/EBPa (7). In chronic inﬂammatory diseases, the
proliferation of human B cells and their differentiation
into immunoglobulin-secreting cells is inﬂuenced by
IL-17 and the B cell-activating factor (BAFF) (51).
Twist1 was identiﬁed as the central mediator of the
effects of IL-17 and BAFF by protecting B-cells from
apoptosis through the induction of the anti-apoptotic
genes Twist2 and Blf-1 (51). It is important to note that
after Twist2 induction, Twist1 levels decrease while Twist2
levels are maintained, therefore the sequential induction of
Twist1 followed by Twist2 and Bﬂ-1 suggest that Twist2
and Bﬂ-1 are the primary antiapoptotic effectors in B-cell
response (51). Interestingly, Twist2 was found to be
overexpressed in B cells from patients with systemic
lupus erythematosus compared to its expression in B
cells from healthy volunteers (51). The sequential induc-
tion and maintenance of Twist2 levels after Twist1 in
immune system proliferation and response suggests that
Twist2 plays a more critical role in the direct regulation of
inﬂammatory cytokines than Twist1. This may account
for the immune dysfunction observed speciﬁcally in
Twist2 KO mice.
ROLE IN CANCER PROGRESSION AND
METASTASIS
The role of Twist proteins during embryonic development
is exploited in disease by tumor cells. Twist1 is known to
play a role in the migration of neural crest cells during
embryogenesis (52). However, this ability to promote
migration by Twist1 is known to facilitate
epithelial-to-mesenchymal transitions (EMT) (53). This
has been attributed to down regulation of epithelial
markers such as E-cadherin, and up regulation of mesen-
chymal markers such as N-cadherin. In addition, the cell
adhesion protein periostin (POSTN), also involved in
cancer metastasis, is directly activated by Twist1 (54).
Twist1/2 also function as proto-oncogenes by protecting
cells from Myc- and p53-dependent apoptosis (55).
Repression of p53 transactivation is thought to be
mediated by Twist1 inhibition of p300/PCAF (38,55).
Direct regulation of genes involved in cancer progres-
sion has also been observed. AKT2 is a modulator of
Y-box-binding protein 1 (YB-1) function, and both are
central to tumor proliferation (56). Twist1 can up-regulate
the proto-oncogene AKT2 by directly binding to its
promoter (57). Twist1 activation of the YB-1 transcription
factor, involved in cellular proliferation, has also been
observed (56). Additionally, the cyclin-dependent kinase
inhibitor p21, involved in growth arrest, is directly
regulated by both Twist1 and Twist2 in the presence of
E12 (58,59).
Recent evidence has shown that Twist1 can directly
activate miR-199a/214 and miR-10b micro RNAs by
binding to their respective promoters (60,61). Activation
of these micro RNAs by Twist1 leads to repression of
target genes implicated in development and cancer, such
as inhibition of translation of the homeobox D10 mRNA
by miR-10b, resulting in increased expression of the
pro-metastatic gene RHOC (61). The ability of Twist1/2
to inhibit apoptosis and facilitate EMT has been
correlated with poor outcomes in cancer patients having
elevated Twist1/2 expression (62).
A general paradigm of cancer progression is that
cellular senescence and EMT are separate processes and
as such, are regulated independently (63). Twist1
and Twist2 are frequently activated in human cancers
and have also been shown to override oncogene-induced
senescence by inhibiting p53 and Rb tumor suppressor
pathways while at the same time promoting EMT (64).
These ﬁndings challenge the classical view by showing
that overexpression of Twist1 and Twist2 in neoplastic
lesions allows for simultaneous regulation of cellular
senescence and EMT (63,64).
CONCLUDING REMARKS
The complex regulatory pathways orchestrated by both
Twist1 and Twist2 are testament to the importance of
these two gene regulatory proteins. Modes of action
by these proteins include binding to conserved E-box
sequences, recruitment of coactivators or repressors,
dimer pool modulation and inhibition of activator/
repressor function through protein–protein interactions.
Regulatory outcomes of Twist1 and Twist2 are themselves
controlled by spatial-temporal expression, phospho-
regulation and dimer choice. Deregulation of genes that
are targeted by these transcription factors, such as those
involvedinmesenchymalcelllineagedifferentiation,results
in a wide array of human diseases such as Saethre Chotzen
syndrome, Setleis syndrome, chronic inﬂammatory
diseases and cancer. However, due to the paucity of infor-
mation available that directly compares the mechanisms of
gene regulation by Twist1 versus Twist2, the full extent to
which these proteins diverge in function remains to be seen.
We know that these proteins are not entirely redundant
based on the contrasting phenotypes observed in
knockout mice and the fact that dominant mutations in
TWIST1 result in craniosynostosis while recessive muta-
tions in TWIST2 result in facial focal dermal dysplasia
with no apparent bone abnormalities (15,24). However,
we cannot rule out the possibility that compensatory func-
tionality between these two proteins may exist as part of a
biological safeguard to ensure accurate regulation of
certain developmental and mature tissue programs.
In order to further examine the redundancy between
Twist1 and Twist2, gene replacement strategies can be
used to test the extent to which these factors may be inter-
changeable during embryogenesis. This approach has been
used with two other members of the Twist subfamily of
Nucleic Acids Research,2011, Vol.39, No. 4 1183proteins, namely Hand1 and Hand2, to show that they
indeed act via unique transcriptional mechanisms (65).
Dissection of bHLH dimer pool dynamics is expected to
be challenging, as experimental manipulations such as
knockdown and overexpression may inadvertently alter
the balance of these factors. Additionally, overlapping
expression patterns of the Twist subfamily members
could result in heterodimerization between themselves
as seen in the case of Twist1 and Hand2 (6). The potential
for dimerization between Twist1 and Twist2 further
compounds the complexity of bHLH dimer partners.
Therefore, genetic engineering techniques that ensure
physiological expression levels of these proteins and
mutant versions would aid in the elucidation of true
modes of action. These techniques could also be used
for the expression of Twist1- and/or Twist2-tethered
dimers to help illustrate how partner choice can dictate
transcriptional outcomes.
The spatial-temporal expression of Twist1 and Twist2 is
critical to the composition of the bHLH dimer pool within
the cell. Therefore, the signals that dictate the expression
patterns of Twist1/2 must be better understood. There are
several pathways that control their expression, which
include NF-kB and STAT3 mediated cytokine signaling
(45,66), the WNT/b-catenin (67) and TGFb pathways
(68), and induction through hypoxia-inducible factor 1a
(69). However the speciﬁcity by which these pathways
activate these proteins is not well understood.
Except in those cases where Twist1 and 2 mechanisms
have been characterized within single gene contexts, there
are no comprehensive genomic expression or chromatin
binding proﬁles directly comparing these two proteins.
The use of ChIP–Chip and ChIP–Seq technologies
would allow the generation of comprehensive transcrip-
tion factor binding maps across the entire genome that
would facilitate the comparison of binding speciﬁcities
between Twist1 and Twist2 (70). Comprehensive analysis
of the binding locations, chromatin structural features and
post-translational modiﬁcations that inﬂuence the binding
of Twist1 versus Twist2 can also provide insight into the
mechanisms by which each factor regulates transcription.
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